Sudeep Pharma Ltd

Sudeep Pharma Ltd

Sudeep Pharma Ltd has announced its Q1 FY27 earnings conference call transcript, showing a 27% year-on-year revenue growth despite a challenging global environment. The company attributes this growth to broad-based performance across its pharma, food and nutrition, and specialty ingredient businesses. Management highlights operational efficiencies, diversified product portfolio, and strong global customer relationships as key factors in its resilience.

Sudeep Pharma Ltd

Sudeep Pharma Ltd has corrected the number of attendees at its Annual General Meeting (AGM) from 45 to 44, with 5 from the promoter group and 39 from the public.

Sudeep Pharma Ltd

Sudeep Pharma Ltd has uploaded the audio recording of its earnings call held on August 5, 2026, on its website.

Sudeep Pharma Ltd

Sudeep Pharma Ltd held its 37th Annual General Meeting on August 4, 2026, through video conferencing. The meeting was attended by 5 promoter shareholders and 40 public shareholders. The resolutions passed include the adoption of audited financial statements, re-appointment of a director, declaration of dividend, ratification of remuneration to cost auditors, appointment of a secretarial auditor, and approval of employee stock option schemes.

Sudeep Pharma Ltd

Sudeep Pharma Ltd has submitted the newspaper publication of its unaudited financial results for the first quarter ended 30th June 2026, as per Regulation 30 and 47 of the SEBI (LODR) Regulations, 2015. The company has also published a notice regarding the sale of immovable property under the SARFAESI Act, 2002.

Sudeep Pharma Ltd

Sudeep Pharma Ltd submitted a revised Investors Presentation for Q1FY27, highlighting a 27% year-on-year revenue growth, driven by operational excellence and strategic growth initiatives.

Sudeep Pharma Ltd

Sudeep Pharma Ltd has submitted unaudited financials for Q1 2026, with total revenues of Rs. 1,139.55 lakhs and a net loss of Rs. 49.12 lakhs. The financial results of two subsidiaries are included, but are not material to the group.

Sudeep Pharma Ltd

Sudeep Pharma Ltd has announced its unaudited standalone and consolidated financial results for the first quarter ended June 30, 2026, with the Board of Directors considering and approving the results at its meeting held on August 4, 2026.

Sudeep Pharma Ltd

Sudeep Pharma Ltd has submitted the proceedings of its 37th Annual General Meeting held on August 4, 2026, through video conferencing. The meeting was attended by directors, auditors, and shareholders, and the requisite quorum was present. The company secretary welcomed the attendees and introduced the directors present. The chairman informed the members about the attendance, e-voting, and statutory registers. The statutory auditors' report and secretarial auditors' report were also presented, with no qualifications or adverse remarks.

Sudeep Pharma Ltd

Sudeep Pharma Ltd has received a disclosure under SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 from Nuvama Crossover Opportunities Fund regarding a potential acquisition of shares.

Sudeep Pharma Ltd

Sudeep Pharma Ltd schedules earnings call with analysts/investors on August 5, 2026, to discuss Q1FY27 financial results.

Sudeep Pharma Ltd

Sudeep Pharma Ltd has scheduled a board meeting on 4th August 2026 to consider and approve the unaudited financials for the quarter ended 30th June 2026.